My favourite UK share on the entire LSE has fallen 5% in a week! Time to buy?

Harvey Jones has waited for years to buy this brilliant UK share. Has the recent stock market dip finally handed him an opportunity to do so?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The recent FTSE 100 dip has knocked what I think could be the best UK share of the lot, pharmaceutical giant AstraZeneca (LSE: AZN)? Is this my chance to buy it at a rare discount?

As a rule, I fight shy of super soaraway stocks like this one. Sod’s law suggests they’ll crash as soon as I clamber on board. So I’ve shunned AstraZeneca for years, only to watch its share price grow and grow.

Should you invest £1,000 in Tesco right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tesco made the list?

See the 6 stocks

There’s a lot of controversy over CEO salaries, but Astra’s Pascal Soriot has more than justified his by doing a brilliant job since joining in October 2012.

At the start of his tenure, the AstraZeneca share price stood at 2,877p. It peaked at 13,274p a few days before the recent bout of volatility. That’s a rise of 360%. All dividends are on top.

Can it keep climbing like this?

AstraZeneca is comfortably the UK’s biggest company, with a market cap of around £195bn. Oil giant Shell is a distant second at just £157bn. I just wish more LSE-listed businesses could scale up like this one.

The momentum has largely continued with the shares up 16.41% in the last 12 months, although they’re down 5.5% over the week. This doesn’t exactly make them cheap though. AstraZeneca still trades at a whopping 43.03 times earnings. That’s way above the FTSE 100 average of around 15 times.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Can I justify buying at that price? AstraZeneca continues to bomb along, with first-half revenue up 18% to $25.6bn. It also upgraded full-year 2024 guidance, forecasting mid-teens percentage growth in total revenue and core earnings per share.

All the hard work Soriot has put into building the company’s drugs pipeline is paying off with interest. And with the world getting older and sicker, that’s likely to continue. AstraZeneca also enjoys healthy 82% margins on core product sales.

It’s a top FTSE 100 income growth stock

There will always be risks to investing in pharmaceutical stocks. Getting drugs to market is a tortuous process, with potential failure at every stage.

Successful blockbuster treatments eventually come off patent, hitting revenues. Plus there’s the constant risk of litigation, particularly in the US, which can trigger legal claims for hundreds of millions of dollars. That can hammer share prices. As I’ve discovered through my holding in FTSE 100 rival GSK.

AstraZeneca’s dividend yield is relatively low at 1.53%, but that’s mostly down to the rocketing share price. Dividend per share growth has been a little bumpy, but the general direction is upwards, as this table shows.


Chart by TradingView

This is clearly a brilliant company. My problem is that wiser investors than me discovered this yonks ago, and have reaped the rewards.

Despite the recent dip, I won’t be buying. My GSK shares are trading at just 10.57 times earnings while yielding 3.54%. I’ll sit tight, cross my fingers and hope they catch up with AstraZeneca.

But there are other promising opportunities in the stock market right now. In fact, here are:

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

Apple stock is close to 52-week lows. Should I snap it up now?

Jon Smith discusses the double-digit percentage fall in Apple stock last week and weighs up whether now's the time to…

Read more »

Investing For Beginners

2 FTSE 100 gems that rallied last week as the stock market tumbled

Jon Smith flags up a couple of FTSE 100 shares that actually jumped at a time when most of the…

Read more »

Investing Articles

Glencore’s share price is 53% off its 52-week highs. Is it time to consider buying?

Glencore’s share price has tanked due to concerns over an economic slowdown. Is this an amazing buying opportunity for long-term…

Read more »

Investing Articles

Forecast: in 1 year, the Marks and Spencer share price could be…

The Marks and Spencer share price has hit its highest point since 2016 after more than doubling under the new…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Down 34%, does IAG’s share price look an unmissable bargain to me now?

IAG’s share price had fallen a long way even before the latest market rout, but this may mean a bargain-basement…

Read more »

Investing Articles

Forecast: in 1 year, the HSBC share price could be…

The HSBC share price is approaching a 20-year high under its new CEO as he targets $1.5bn of savings. Here…

Read more »

Investing Articles

Forecast: in 1 year, the Barclays share price could be…

Barclays’ share price has more than tripled in the last five years as higher interest rates push up margins. But…

Read more »

Investing Articles

This FTSE 100 heavyweight’s yield is forecast to rise to 8% by 2027 and it looks 60%+ undervalued to me too!

This FTSE financial gem looks very undervalued to me and its yield is projected to rise to well over my…

Read more »